Evidence map›Paper›PMID 36282207›Full record

ArticleBritish journal of haematology2023

United we stand, divided we fall. Multicentre standardization of measurable residual disease assessment in acute leukaemia is the way forward.

Gaurav Chatterjee, Nikhil Patkar

Abstract readMulticenter StudyComment
PubMed Publisher
In one paragraph

Article in British journal of haematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Gaurav ChatterjeeHaematopathology Laboratory, ACTREC, Tata Memorial Centre, Navi Mumbai, India.ORCID 0000-0002-6505-7898
Nikhil PatkarHaematopathology Laboratory, ACTREC, Tata Memorial Centre, Navi Mumbai, India.ORCID 0000-0001-9234-2857
Tata Memorial Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Assessment of measurable residual disease (MRD) using multiparameter flow cytometry in precursor B-cell acute lymphoblastic leukaemia (ALL) is routine. However, studies on the harmonization of laboratory techniques as well as on the interpretation of results are limited. Here, Ikoma-Colturato and colleagues from Brazil demonstrate multicentric standardization of B-ALL MRD using EuroFlow protocols. Commentary on: Ikoma-Colturato et al., Multicentric standardization of minimal/measurable residual disease in B-cell precursor acute lymphoblastic leukaemia using next-generation flow cytometry in a low/middle-level income country. Br J Haematol 2023;200:381-384.

Indexed as

Burkitt LymphomaLeukemia, Myeloid, AcutePrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaFlow CytometryHumansNeoplasm, Residualacute lymphoblastic leukaemiameasurable residual diseasemulticentre studiesmultiparameter flow cytometrystandardization

Identifiers

PMID36282207
OpenAlexW4307232187

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.